Investigation of Cycloserine as a Smoking Cessation Treatment
Information source: Baylor College of Medicine
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Nicotine Addiction
Intervention: Cycloserine (Drug); Placebo (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: Baylor College of Medicine
Summary
Psychosocial treatments for drug abuse benefit some patients (Rawson et al 2004), but there
is an urgent need for new treatment approaches that can improve treatment outcomes. One new
approach involves facilitation of extinction of conditioned responses through the use of
d-cycloserine, a partial agonist at the NMDA glycine site. This approach has proved useful
for the treatment of several anxiety disorders. For example, treatment with d-cycloserine
enhanced the efficacy of behavioral treatments for acrophobia (Ressler et al 2004) and
social phobia (Hofmann et al 2006) by enhancing extinction of conditioned fear responses.
This suggests that d-cycloserine has potential to enhance the efficacy of behavioral
treatments for drug dependence by enhancing extinction of conditioned responses to drug
cues. In this Phase I Cutting-Edge Basic Research Awards (CEBRA) application we propose a
proof-of-concept study to examine effects of treatment with d-cycloserine for facilitating
extinction of craving provoked by exposure to cigarette smoking cues. The benefits of this
treatment approach together with cognitive behavioral treatment for reducing cigarette
smoking will then be determined. Smoking cues will be presented using an established virtual
reality simulator(Bordnick et al 2004; Bordnick et al 2005a)
Clinical Details
Official title: Cycloserine Enhancement of Extinction Learning
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary outcome: The effects of four weeks of single dose treatment with d-cycloserine or placebo on craving elicited by exposure to "virtual reality" smoking cues
Secondary outcome: The effects of four weeks of single dose treatment with d-cycloserine or placebo, exposure to virtual reality smoking cues, and provision of manual-driven cognitive behavioral treatment on frequency of cigarette smoking and cocaine use
Detailed description:
See brief summary
Eligibility
Minimum age: 18 Years.
Maximum age: 55 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Want to participate in a treatment aimed at helping them stop smoking cigarettes
- Be English-speaking volunteers between 18-55 years of age
- Meet DSM-IV TR criteria for current nicotine dependence and smoke >10 cigarettes per
day for the past year
- Meet DSM-IV TR criteria for cocaine dependence, but not seeking treatment for cocaine
dependence at the time of study
- Have a medical history and brief physical examination demonstrating no clinically
significant contraindications for study participation, in the judgment of the
admitting physician and the principal investigator
Exclusion Criteria:
- Meet DSM-IV TR criteria for abuse or dependence on alcohol or other drugs, except for
nicotine and cocaine
- Have psychiatric disorders, such as: current major depression as assessed by SCID;
lifetime history of schizophrenia, other psychotic illness, or bipolar illness as
assessed by SCID; current organic brain disease or dementia assessed by clinical
interview; history of or any current psychiatric disorder which would require ongoing
treatment or which would make study compliance difficult; history of seizure disorder
or severe head injury
- Have evidence of untreated or unstable medical illness including: neuroendocrine,
autoimmune, renal, hepatic, or active infectious disease
- Be pregnant or nursing. Female participants must either be unable to conceive (i. e.,
surgically sterilized, sterile, or post-menopausal) or be using a reliable form of
contraception (e. g., abstinence, birth control pills, intrauterine device, condoms,
or spermicide). All females must provide negative pregnancy urine tests before study
entry and at the end of study participation
- Have no history of adverse response to d-cycloserine
- Have any other illness, condition, or use of medications, which in the opinion of the
P. I. and/or the admitting physician would preclude safe and/or successful completion
of the study
Locations and Contacts
Michael E. DeBakey VA Medical Center, Houston, Texas 77030, United States
Additional Information
Starting date: May 2009
Last updated: July 25, 2012
|